CTOs on the Move

Kaken Pharmaceuticals

www.kaken.com

 
Kaken Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.kaken.com
  • 245 Park Ave New York
    New York, NY USA 10167
  • Phone: 212.372.8910

Executives

Name Title Contact Details

Similar Companies

Shape Therapeutics

Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy.

On Target Laboratories

Our illuminating molecules enhances the doctors ability to see disease tissue clearly improving their ability to treat cancer, autoimmune and other diseases.

Advanced Research Projects Agency for Health

The Advanced Research Projects Agency for Health (ARPA-H) is committed to solving the most challenging problems in health by developing research programs dedicated to urgency, excellence and honesty. Part of the U.S. Department of Health and Human Services, ARPA-H aims to accelerate breakthroughs that empower every American to realize their full health potential – turning the seemingly impossible to the possible to the actual. The ARPA model is a continuous cycle of planning, implementing, and evaluating, and we`re looking for the best ideas and the brightest minds to carry out each process. We`re committed to diversity in all its forms.

Stowers Resource Management

Stowers Resource Management is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fore Biotherapeutics

As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.